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ABSTRACT
To compare and predict kinesiophobia and fear avoidance beliefs between athletes with gastrocnemius myofascial pain syndrome
(MPS) and healthy athletes.
Case–control.
Outpatient clinic.] 
Fifty athletes were divided into athletes with chronic gastrocnemius MPS (N = 25) and healthy athletes (N = 25).
Kinesiophobia symptoms total and domain scores (harm and activity avoidance) and levels were determined by the Tampa Scale
of Kinesiophobia (TSK-11). Fear avoidance beliefs total and domain scores (physical and working activities) were measured by the
Fear Avoidance Beliefs Questionnaire (FABQ).
Significant differences (P < 0.05) with a large effect size (d = 0.81–4.22) were found between both groups, with greater kinesio-
phobia symptom scores for the TSK-11 activity avoidance domain and total scores, and greater fear avoidance beliefs scores for
the FABQ physical and working activities domains and total scores of athletes with gastrocnemius MPS with respect to healthy
athletes. TSK-11 total score showed[AQ4] a prediction model (R2 = 0.256) based on the FABQ total score. The FABQ total score
showed a prediction model (R2 = 0.741) based on gastrocnemius MPS presence (R2 = 0.665), levels of kinesiophobia (R2 = 0.052),
and height (R2 = 0.025).
Greater kinesiophobia levels, greater total and activity avoidance domain scores (but not for the harm domain), and greater fear
avoidance beliefs total and domain scores (work and physical activity) were shown for athletes with gastrocnemius MPS vs
healthy athletes. Higher kinesiophobia symptoms were predicted by greater fear avoidance beliefs in athletes. Greater fear avoid-
ance beliefs were predicted by the presence of gastrocnemius MPS, higher levels of kinesiophobia, and lower height in athletes.




Myofascial pain syndrome (MPS) may be defined as and considered a common musculoskeletal condition that com‐
prises signs and symptoms due to the presence of myofascial trigger points (MTrPs). These points present hyperirrita‐
ble nodules in skeletal muscular taut bands, producing typical local and/or referred pain in conjunction with other
autonomic, motor[AQ5], and/or sensitive alterations [1, 2].
Psychological conditions such as kinesiophobia and pain-related fear seem to be commonly presented in athletes
suffering from pain alterations, playing a key role in the intensity and frequency of soreness as well as having physi‐
cal and/or psychological consequences in athletic populations [3–5]. Indeed, athletes who suffer from patellofemoral
pain present higher kinesiophobia with respect to healthy controls [6]. In addition, athletes with a history of anterior
cruciate ligament reconstruction who have not participated in sports present greater fear avoidance beliefs with re‐
spect to athletes with a history of anterior cruciate ligament reconstruction who have participated in sports or healthy
athletes. Also, athletes with a history of anterior cruciate ligament reconstruction who have participated in sports
present greater fear avoidance related to work and physical activities compared with healthy athletes [5]. According
to these findings, additional psychosocial care should be specially directed toward controlling fear avoidance beliefs
and kinesiophobia in athletes suffering from pain disorders and returning to sports [5, 6]. Despite gastrocnemius
MTrPs having recently been a main focus of intervention in athletes [7, 8], there is a lack of research evidence re‐
garding fear avoidance beliefs and kinesiophobia in athletes suffering from gastrocnemius MPS.
Indeed, MTrPs may be considered peripheral pain generators for general and regional musculoskeletal pain condi‐
tions [9, 10] associated with local ischemia, low pH, and release of inflammatory mediators [11]. Regarding MTrPs’
clinical diagnosis, MTrPs may be divided into latent or active. Both types seem to present the same characteristics,
although only active MTrPs are associated with spontaneous pain and patients’ pain recognition during stimulation
[1, 2, 9, 10]. MTrPs show a high prevalence (from 13% to 30%) in gastrocnemius muscles under triceps surae muscu‐
loskeletal alterations [12, 13]. Furthermore, lower limb musculoskeletal conditions are the reason for up to one-third
of medical sport consultations [14]. Concretely, gastrocnemius musculoskeletal alterations are the most common inju‐
ries in the lower limb muscles of athletes during training (up to 39%) and competition (up to 46%) [15]. [AQ6]
According to prior studies, the role of kinesiophobia and fear avoidance beliefs could be important in MPS inter‐
ventions [16–18]. A high prevalence of gastrocnemius muscle injuries have been previously shown in athletes [14,
15, 19], including frequently active MTrP-generating MPS [12, 13]. Consequently, MPS interventions have been re‐
cently applied to MTrPs of gastrocnemius in athletes [7, 8]. Fear avoidance beliefs and kinesiophobia may play a key
role in athletes suffering from pain conditions [5, 6]. According to these considerations, the influence of fear avoid‐
ance beliefs and kinesiophobia needs to be deeply studied in athletes suffering from gastrocnemius MPS. Thus, the
main purpose of this research was to compare kinesiophobia symptoms and levels between athletes suffering from
gastrocnemius MPS and healthy athletes. Furthermore, another secondary aim was to compare fear avoidance belief
scores between athletes suffering from gastrocnemius MPS and healthy athletes. Finally, other secondary aims were
to predict kinesiophobia symptoms according to descriptive data, fear avoidance scores, and MPS presence, as well
as predicting fear avoidance beliefs based on descriptive data, kinesiophobia scores and levels, and MPS presence.
Therefore, it was hypothesized that athletes suffering from gastrocnemius MPS could exhibit higher kinesiophobia
symptoms and levels and fear avoidance belief scores compared with healthy athletes. Furthermore, it was hypothe‐
sized that kinesiophobia symptom scores could be predicted based on descriptive data, fear avoidance scores, and
MPS presence, and that fear avoidance belief scores could be predicted based on descriptive data, scores and levels of
kinesiophobia, and MPS presence.
Methods
Design
The study design was carried out as a case–control secondary analysis according to the STrengthening the Report‐
ing of OBservational studies in Epidemiology (STROBE) guidelines [20, 21]. Indeed, kinesiophobia symptoms and
fear avoidance beliefs were analyzed comparing athletes suffering from MPS vs healthy athletes using self-reported
questionnaires. The Ethical Committee of The Princess University Hospital (CEIm 22/18) approved this study. Be‐
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fore starting this study, athletes signed the informed consent form. Finally, the Helsinki Declaration and human exper‐
imentation ethical requirements were respected during the study’s course [22].
Calculation of Sample Size
Kinesiophobia score was considered the main outcome measurement in order to perform the sample size calcula‐
tion, as athletes suffering from musculoskeletal pain conditions in the lower limbs seemed to present greater kinesio‐
phobia symptoms with respect to healthy controls [6]. G*Power software (version 3.1.9.2; Dusseldorf University,
Dusseldorf, Germany) was utilized to perform the sample size calculation using the between two independent groups
difference [23]. Kinesiophobia total score, assessed with the Spanish validated Tampa Scale of Kinesiophobia–11
items (TSK-11) [24, 25] from a pilot study (N = 17) with two groups described using mean ± SD, including seven
athletes suffering from gastrocnemius MPS (22.71 ± 4.92 points) and seven healthy athletes (19.14 ± 4.71 points),
was utilized to perform the sample size calculation. In addition, an effect size of d = 0.74, error probability of
α = 0.05, 95% confidence interval, power of 1-β error probability = 0.80), one-tailed hypothesis, and allocation ratio
of N2/N1 = 1 were used to calculate the sample size. Thus, a total sample size of 48 athletes, 24 athletes for each
group, was determined. According to a possible 5% loss to follow-up, a total sample size of 50 athletes, divided into
25 athletes suffering from MPS and 25 healthy athletes, was used.
Sample
A total sample of 50 athletes was matched pairwise for descriptive data and recruited by a consecutive conven‐
ience sampling method from 2018 to 2019. Athletes were divided into cases, including patients suffering from chron‐
ic gastrocnemius MPS for more than three months (N = 25; gastrocnemius MPS group), and controls, including
healthy matched paired participants (N = 25; healthy group).
Athletes who carried out level II (moderate) or III (vigorous) physical activity according to scores >600
MET/min/wk, measured by the International Physical Activity Questionnaire (IPAQ), with an age range from 18 to
65 years were included in the study [26]. First, the control group included healthy athletes matched pairwise for de‐
scriptive data (sociodemographic, physical activity, and sport category characteristics) without MPS or other condi‐
tions at least for the previous year [27, 28]. Second, the case group was comprised of athletes suffering from bilateral
or unilateral gastrocnemius MPS suffering from persisting and chronic pain for more than three months and present‐
ing at least one active MTrP in the gastrocnemius diagnosed by an experienced physical therapist according to a
standardized manual palpation procedure with good agreement reliability (κ = 0.63) [29]. The presence of three posi‐
tive signs/symptoms from four possible items, including 1) sensible knot, 2) taut band, 3) pain pattern recognition
during stimulation by palpation and presence of spontaneous pain (mandatory criterion for an active MTrP), and 4)
ankle dorsiflexion limitation at full stretch, were used for active MTrP diagnosis [1, 2, 30].
Systemic conditions, neurological disorders, arthritis, neoplasms, autoimmune alterations, vascular pathologies,
neuropathic conditions (e.g., radiculopathy), fractures, tendinopathies, sprains, surgeries, lower limb dysmetria (dif‐
ference >1 cm between both lower limbs), mental disorders, and cognitive alterations were assessed by the question‐
naires during the study’s course [12, 13, 31].
Descriptive Data
Body mass index (BMI was calculated by the Quetelet index as weight/height2 and measured as kg/cm2) [32],
height (measured by cm), weight (measured by kg), sex (categorized as male or female), age (measured by years),
main sport category performance (categorized as running, fitness, soccer, athletics, or paddle), pain intensity (meas‐
ured by the visual analog scale) [33], and pain location (categorized as left, right, or bilaterally gastrocnemius) were
collected [27].
In addition, the International Physical Activity Questionnaire (IPAQ) was self-reported by all study participants
[26]. This questionnaire was used to report physical activity scores and levels by the index of metabolic equivalents
per minutes per week (MET/min/wk); scores were categorized into moderate physical activity (600–1,500
MET/min/wk) or vigorous physical activity (≥1,500 MET/min/wk) level, respectively. This tool showed good psy‐
chometric properties for repeatability (Spearman’s rho = 0.80) and criterion validity (median rho = 0.30) [34].
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Outcome Measurements
The main outcome measurement was the kinesiophobia total score, assessed with the Spanish validated Tampa
Scale of Kinesiophobia–11 items [24, 25]. Secondary outcome measurements were harm and activity avoidance kine‐
siophobia domain scores as well as kinesiophobia levels assessed with the TSK-11 [24, 25], and the total scores as
well as working and physical activity domain scores of the fear avoidance beliefs symptoms measured with the Span‐
ish validated Fear Avoidance Beliefs Questionnaire (FABQ) [35, 36]. Both tools were self-reported by case and con‐
trol athletes with the support of a psychologist with clinical experience of 10 years in order to clarify doubts when
filling out these questionnaires.
Tampa Scale of Kinesiophobia–11 Items
The Spanish validated TSK-11 was self-reported by case and control athletes to determine the kinesiophobia
symptoms total score, harm and activity avoidance kinesiophobia domain scores, and categorization into levels of
fear of movement [24, 25]. Kinesiophobia may be defined as an initial adaptive response to threat that may produce
maladaptive and avoidance behaviors, increasing fear and pain and producing limited activity and fear of movement
[37–39]. Fear of movement may be a predictor of future disability [37]. This scale presented a total kinesiophobia
symptoms score and two domains: activity avoidance and harm. This tool was scored by a four-point Likert scale,
with higher scores representing greater fear of pain, movement, and injury. TSK-11 total scores were divided into
levels of fear of movement: no fear (from 0 to 17 points), slight fear (from 18 to 24 points), moderate fear (from 25 to
31 points), severe fear (from 32 to 38 points), and maximum fear (from 39 to 44 points) [24, 25]. Acceptable psycho‐
metric properties have been shown with good internal consistency (Cronbach’s α = 0.78), test–retest (intraclass corre‐
lation coefficient [ICC] = 0.82), standard error of measurement (SEM = 3.16), responsiveness (−1.19), minimum
clinically important difference (MCID = 4.80), and minimum detectable change (MDC = 5.60) [24, 25, 40–42].
Fear Avoidance Beliefs Questionnaire
The FABQ was used in the present study to evaluate the influence of fear avoidance beliefs on daily disability
secondary to pain presence in athletes who carry out physical activity while suffering from a chronic MPS condition
[43, 44]. This tool provided a total score of fear avoidance beliefs symptoms and was divided into two domains, fear
avoidance beliefs related to physical activity (FABQ-PA) and working activity (FABQ-W), including a total of 16
items in a Likert-type scale from 0 to 6 points, with 0 = “totally disagree” and 6 = “totally disagree.” The total range
varied from 0 to 55 points. Higher score values showed greater fear of pain and physical activity, resulting in more
avoidance behaviors. The Spanish validated FABQ showed acceptable psychometric properties, with a Cronbach α
internal consistency of 0.91, an ICC of 0.96, and a Kappa value mean for all items of 0.74 [45].
Statistical Analysis
The Statistical Package for Social Sciences (version 24.0; IBM Corp., Armonk, NY, USA) was used to analyze all
data, with an α error of 0.05 and a P value <0.05 considered statistically significant, in line with the detailed sample
size calculation.
For quantitative data analyses, Shapiro-Wilk tests were used to calculate normality distributions. Data were ana‐
lyzed as parametric if they were adjusted to normal distributions showing a P value ≥0.05 on the Shapiro-Wilk test.
Data were analyzed as nonparametric if they were not adjusted to normal distributions showing a P value <0.05 on
the Shapiro-Wilk test. Parametric data were described as mean ± SD and range (minimum to maximum values), and
the differences between athletes with gastrocnemius MPS and healthy athletes were analyzed by the Student t test for
independent samples according to Levene’s test for equality of variances. Nonparametric data were described as me‐
dian ± SD and range (minimum to maximum values), and the differences between athletes with gastrocnemius MPS
and healthy athletes were analyzed by the Mann-Whitney U test for independent samples. For all outcome measure‐
ments, effect size was calculated by Cohen’s d and divided into very small (d < 0.20), small (d = 0.20–0.49), medium
(d = 0.50–0.79), and large effect sizes (d > 0.8) [46].
Considering categorical data analyses, data were described as frequency (No.) and percentage (%), and the differ‐
ences between athletes with gastrocnemius MPS and healthy athletes were analyzed according to the Fisher exact test
for dichotomous data or the chi-square test for polytomous data.
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Afterward, multivariate predictive analyses were carried out by two linear regression models. Both linear regres‐
sion models were performed by applying stepwise selection methods and R2 coefficients to establish the quality of
adjustment [47]. The first linear regression model used descriptive data such as sex, age, height, weight, BMI, IPAQ
scores and categories, main sport category performance, and gastrocnemius MPS presence (case or control group,
fear avoidance beliefs measured by the FABQ domains (related to physical and working activities) and total score as
independent variables. Kinesiophobia symptoms measured by TSK-11 total scores were included as the dependent
variable. The second linear regression model also used descriptive data such as sex, age, height, weight, BMI, IPAQ
scores and categories, main sport category performance, gastrocnemius MPS presence (case or control group), and
kinesiophobia symptoms and levels measured by the TSK-11 domains (related to harm and activity avoidance) and
total score and their categorization into levels of fear (no, slight, moderate, severe, and maximum fear levels) as inde‐
pendent variables. Fear avoidance beliefs measured by the FABQ total score were included as the dependent variable.
Pre-established parameters of the F probability were Pin = 0.05 and Pout = 0.10, and P values <0.05 were considered
statistically significant according to all statistical analyses.
Results
Descriptive Data
From a total sample of 72 athletes evaluated for eligibility, 22 athletes were excluded due to presence of systemic
disorders such as diabetes (N = 3), radiculopathy (N = 1), vascular alterations (N = 3), rheumatoid arthritis (N = 4),
prior lower limb fractures and/or surgeries (N = 4), Achilles and/or patellar tendinopathy (N = 3), level I physical
activity according to the IPAQ (N = 2), and absence of at least one active MTrP in the gastrocnemius muscle (N = 2)
according to the flow diagram (Figure 1). A total sample of 50 athletes was included in this study and divided into
athletes with chronic gastrocnemius MPS (N = 25; MPS case group) and healthy athletes (N = 25; healthy control
group). Descriptive data did not show statistically significant differences (P > 0.05) between athletes with gastrocne‐
mius MPS vs healthy athletes for sex (13 women and 12 men vs 10 women and 15 men, P = 0.571), age
(38.00 ± 11.84 vs 41.00 ± 11.72 years, P = 0.509), weight (69.76 ± 10.70 vs 68.28 ± 14.48 kg, P = 0.683), height
(1.71 ± 0.10 vs 1.69 ± 0.10 m, P = 0.580), BMI (23.64 ± 2.44 vs 23.40 ± 2.87 kg/cm2, P = 0.759), IPAQ score
(2,946.00 ± 2,938.50 vs 2,277.00 ± 3,746.50 MET/min/wk), IPAQ category (seven moderate and 18 vigorous vs 11
moderate and 14 vigorous physical activity level), and main sport category performance (six running, 10 fitness, four
soccer, two athletics, and three paddle vs nine running, 13 fitness, two soccer, one athletics, and zero paddle sport),
respectively. In addition, the group of athletes suffering from MPS showed a pain intensity of 5.70 ± 3.05 points,
located at the right gastrocnemius in 10 athletes, left gastrocnemius in three athletes, and bilaterally in 12 athletes.
Figure 1 Flow diagram.[AQ14]
Figure 2 Distribution graph showing TSK-11 scores and kinesiophobia cutoff scores showing levels of fear such as no fear (0–17
points), slight fear (18–24 points), moderate fear (25–31 points), severe fear (32–38 points), and maximum fear (39–44 points)
levels for athletes suffering from gastrocnemius MPS and healthy athletes. MPS = myofascial pain syndrome; TSK-11 = Tampa
Scale of Kinesiophobia–11 items. [AQ13]
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Kinesiophobia
Statistically significant differences (P < 0.01) with a large effect size (d = 0.81–0.87) were shown between the
groups, detailing greater kinesiophobia symptom scores for the TSK-11 activity avoidance domain and total scores of
athletes suffering from gastrocnemius MPS with respect to healthy athletes, although there were no statistically sig‐
nificant differences (P = 0.145), with a small effect size (d = 0.41) for the harm domain scores of the kinesiophobia
symptom scores. In addition, statistically significant differences (P = 0.035) were shown for TSK-11 categorization
presenting higher levels of fear of movement for the athletes with gastrocnemius MPS with respect to healthy athletes
(Table 1; Figure 1).
Table 1 Kinesiophobia symptom scores and levels according to the domains, total score, and categorization of TSK-11 for athletes
suffering from gastrocnemius MPS, healthy athletes, and the total sample
Kinesiophobia (TSK-11) Total Group Gastrocnemius MPS
Cases
Healthy Controls P MPS vs
Healthy
Effect Size, d
(N = 50) (N = 25) (N = 25)
Activity avoidance 12.00 ± 5.00 14.00 ± 7.50 11.00 ± 3.50 0.008* 0.87
(6.00–24.00) (8.00–24.00) (6.00–19.00)
Harm 7.00 ± 4.00 8.00 ± 3.50 7.00 ± 5.00 0.145* 0.41
(4.00–16.00) (4.00–16.00) (4.00–14.00)
Total score 19.00 ± 9.50 21.00 ± 9.00 17.00 ± 5.50 0.007* 0.81
(10.00–38.00) (12.00–38.00) (10.00–29.00)
Fear levels No (0–17) 19 (38%) 5 (20%) 14 (56%) 0.035† N/A
Slight (18–24) 17 (34%) 10 (40%) 7 (28%)
Moderate (25–31) 11 (22%) 7 (28%) 4 (16%)
Severe (32–38) 3 (6%) 3 (12%) 0 (0%)
Maximum (39–44) 0 (0%) 0 (0%) 0 (0%)
P values <0.05 for a 95% confidence interval were considered statistically significant (bold).
MPS = myofascial pain syndrome; N/A = not applicable; TSK-11 = Tampa Scale of Kinesiophobia–11 items.
*Median ± interquartile range and range (minimum–maximum) and Mann-Whitney U test were used.
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†Frequency and percentage (%) and chi-square test (χ2) were used.
The TSK-11 total score showed a statistically significant prediction model (R2 = 0.256) based on the FABQ total
score (R2 = 0.256, β = +0.163, F[1, 48] = 16.557, P < 0.001), predicting greater kinesiophobia symptom scores based
on higher fear avoidance beliefs scores. Thus, the rest of the independent variables were excluded (P > 0.05) from the
described prediction model due to TSK-11 total scores, as dependent variables were not predicted by sex, age, height,
weight, BMI, IPAQ scores and categories, main sport category performance, gastrocnemius MPS presence (case or
control group), or FABQ domains (related to physical and working activities) as independent variables following pre-
established F probability parameters (Table 2).
Table 2 Linear regression model for the kinesiophobia total scores multivariate prediction between athletes suffering from gastro‐
cnemius MPS and healthy athletes
Parameter Model R2 Change Model R2
TSK-11 total score 17.509   
 +0.163 × FABQ total score 0.256* 0.256
FABQ = Fear Avoidance Beliefs Questionnaire; MPS = myofascial pain syndrome; TSK-11 = Tampa Scale of Kinesi‐
ophobia – 11 items.
*P values <0.001 for a 95% confidence interval are shown.
Fear Avoidance Beliefs
Statistically significant differences (P < 0.001) with a large effect size (d = 1.46–4.22) were shown between the
groups, detailing greater fear avoidance beliefs scores for the FABQ physical and working activity domains and total
scores of athletes suffering from gastrocnemius MPS with respect to healthy athletes (Table 3).
Table 3 Fear avoidance beliefs according to the FABQ domains and total scores of athletes suffering from gastrocnemius MPS,
healthy athletes, and total sample
Fear Avoidance Beliefs
(FABQ)
Total Group Gastrocnemius MPS
Cases




(N = 50) (N = 25) (N = 25)
Physical activity 7.50 ± 15.75 18.00 ± 5.00 3.00 ± 4.50 <0.001* 4.22
(0.00–25.00) (8.00–25.00) (0.00–7.00)
Working activity 2.00 ± 17.25 17.00 ± 21.50 0.00 ± 2.00 <0.001* 1.46
(0.00–55.00) (0.00–55.00) (0.00–4.00)
Total score 10.00 ± 31.75 33.00 ± 24.50 3.00 ± 5.00 <0.001* 2.45
(00.00–79.00) (8.00–79.00) (0.00–10.00)
P values <0.05 for a 95% confidence interval were considered statistically significant (bold).
FABQ = Fear-Avoidance Beliefs Questionnaire; MPS = myofascial pain syndrome.
*Median ± interquartile range and range (minimum–maximum) and Mann-Whitney U test were used.
The FABQ total score showed a statistically significant prediction model (R2 = 0.741) based on the gastrocnemius
MPS presence according to groups (R2 = 0.665, β = +27.642, F[1, 48] = 95.097, P < 0.001), levels of fear of move‐
ment according to TSK-11 categorization (R2 = 0.052, β = +4.358, F[1, 47] = 8.613, P = 0.005), and height (R2 =
0.025, β = –0.297, F[1, 46] = 4.358, P = 0.042), predicting greater fear avoidance belief scores for athletes suffering
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from gastrocnemius MPS, higher kinesiophobia levels, and lower height of athletes. Thus, the rest of the independent
variables were excluded (P > 0.05) from the described prediction model due to FABQ total scores as dependent varia‐
bles not being predicted by sex, age, weight, BMI, IPAQ scores and categories, or main sport category performance;
nor were TSK-11 domains or total scores (related to harm and activity avoidance) used as independent variables due
to the pre-established F probability parameters (Table 4). [AQ7]
Table 4 Linear regression model for the fear avoidance beliefs total scores multivariate prediction between athletes suffering from
gastrocnemius MPS and healthy athletes
Parameter Model R2 Change Model R2
FABQ total score 50.723   
 +27.642 × MPS presence (group) 0.665**  
+4.713 × fear levels (TSK-11 categorization) 0.052*  
–0.297 × height (m) 0.025* 0.741
Multiplay: fear levels (TSK-11 categorization as: no fear = 0, slight fear = 1, moderate fear = 2, severe fear = 3,
maximum fear = 4); MPS presence (healthy athletes group = 0, MPS athletes group = 1).
FABQ = Fear Avoidance Beliefs Questionnaire; MPS = myofascial pain syndrome; TSK-11 = Tampa Scale of Kinesi‐
ophobia – 11 items.
*P values <0.05 for a 95% confidence interval are shown.
**P values <0.001 for a 95% confidence interval are shown.
Discussion
To the authors’ knowledge, this research study may be considered the first case–control study showing greater ki‐
nesiophobia levels, kinesiophobia total scores, and activity avoidance domain scores of the TSK-11 for athletes with
gastrocnemius MPS compared with healthy athletes. Nevertheless, harm domain scores of TSK-11 did not show stat‐
istical differences between the groups. In addition, greater fear avoidance beliefs total scores and fear avoidance be‐
liefs related to work and physical activity domains were present in athletes suffering from gastrocnemius MPS com‐
pared with healthy athletes. These findings were in accordance with previous studies evaluating kinesiophobia and
fear avoidance beliefs in athletes suffering from other musculoskeletal conditions such as patellofemoral pain [6] and
anterior cruciate ligament reconstruction [5]. In addition, prior studies have related MPS to kinesiophobia and fear
avoidance beliefs, although in nonathletic populations and other myofascial pain conditions different from gastrocne‐
mius such as temporomandibular disorders [48], fibromyalgia and chronic fatigue syndrome [49], low back pain,
whiplash-associated disorders [50], migraine [51], and chronic mechanical neck pain [52].
Indeed, the activity avoidance domain of the TSK-11 showed statistically significant differences between both
groups due to athletes with MPS presenting more beliefs that activities provoking soreness should be avoided com‐
pared with healthy athletes, whereas the harm domain of the TSK-11 did not show statistical differences between
groups due to athletes presenting similar beliefs about soreness being a sign of bodily damage compared with healthy
athletes [37–39]. A plausible explanation for these differences on kinesiophobia domains could be that fear of move‐
ment related to physical activity may play a key role in training and competition of athletes, whereas fear of move‐
ment related to harm could be a secondary issue for athletes who believe that soreness does not present a close rela‐
tionship with bodily damage [5, 6].
According to the first prediction model (Table 2), fear avoidance beliefs positively predicted kinesiophobia symp‐
toms in athletes. These findings are in accordance with prior studies reporting that fear avoidance beliefs and kinesio‐
phobia are inter-related and that their relationship plays a key role in athletes who suffer from pain conditions [5, 6].
Regarding the second prediction model (Table 4), the presence of gastrocnemius MPS, greater levels of fear of move‐
ment, and lower height predicted more fear avoidance beliefs in athletes. The presence of gastrocnemius MPS was
shown as a powerful predictor of fear avoidance beliefs, which may be due to nociceptive inputs in athletes suffering
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from MPS increasing the neural synaptic excitability of the central nervous system nociceptive pathways [53], ex‐
panding referred pain patterns of active MTrPs in gait cycle propulsion muscles such as the gastrocnemius [7, 8],
increasing fear avoidance beliefs and levels of fear of movement in athletes [5, 6]. Despite the lowest R2 coefficient,
lower height predicted higher fear avoidance beliefs in athletes. A prior study has reported a relationship between
dynamic stability evaluated by functional reaching and multidirectional speed in athletes who present high movement
demands or muscle recruitment [54]. Nevertheless, our findings relating height to fear avoidance beliefs have not
been previously reported in the sport medicine literature, and further studies are needed in order to further explain
this issue.
Future Studies
Future clinical trials should include kinesiophobia and fear avoidance beliefs as covariables to determine the clini‐
cal effectiveness of psychological or physical therapy treatments such as dry needling or ischemic compression in
athletes suffering from gastrocnemius MPS [7, 8]. In addition, the influence of fear of movement and fear avoidance
beliefs should be considered in future studies about clinical outcomes or return to sports in athletes suffering from
chronic gastrocnemius MPS and Achilles tendinopathies [7, 55]. Finally, future studies should be carried out to deter‐
mine foot orthoses’ effectiveness in order to reduce kinesiophobia and fear avoidance beliefs in athletes with gastro‐
cnemius MPS, as prior studies have shown a pain reduction in other musculoskeletal conditions such as low back
pain [56], knee pain [57], forefoot pain [58], and rheumatoid arthritis [59].
Limitations
Some limitations should be acknowledged in the present study. First, the consecutive sampling method may be a
limitation. Second, socioeconomic data and civil and working status were not collected. Finally, despite prior studies’
recommendations mainly focused on MPS and active MTrPs according to the good reliability of diagnosis by a stand‐
ardized manual palpation procedure [29], another possible limitation was that latent MTrPs’ presence was not as‐
sessed in the present study and should be considered in the design of future studies, as latent MTrPs have been dem‐
onstrated to be a key focus of MPS sensitization [60].
Conclusions
Greater kinesiophobia levels, total scores, and activity avoidance domain scores (but not for the harm domain), as
well as greater fear avoidance beliefs total scores and fear avoidance beliefs related to work and physical activity
domains, were shown for athletes suffering from gastrocnemius MPS compared with healthy athletes. Indeed, higher
kinesiophobia symptoms were predicted by greater fear avoidance beliefs in athletes. In addition, greater fear avoid‐
ance beliefs were predicted by the presence of gastrocnemius MPS, higher levels of kinesiophobia, and lower height
in athletes.
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